


Abstract

A variety of genetic markers and genomic pattern-signatures may provide predictions and insights into the molecular basis of diseases, individual susceptibilities, likelihood of severity, optimal therapeutic approach, new therapeutic avenues, and clinical outcome. Since most common diseases have been shown to be influenced by inherited genetic variations, mapping variations across the human genome for many individuals will have a tremendous impact on our approach to medicine. New developments in genotyping techniques and bioinformatics—enabling detection of single-nucleotide and other polymorphisms—may lead to extensive changes in our understanding of human biology. We have adopted an integrative approach to the analysis of potential polymorphism impact by developing a set of interconnected systems (PolyDoms: <http://polydoms.chmc.org>; PathoGene: <http://abstrainer.cchmc.org>, GenomeTrafac: <http://genometrafac.cchmc.org/>), to allow for linkage of genetic polymorphisms to biological processes and pathways operative in diseases, and that influence response to therapy. To approach this, we have divided genomic medicine into two separate networks: gene networks and disease networks. Diseases can be related to each other on the basis of shared etiology, pathophysiology, clinical signs and symptoms, or cellular phenotypes. Genes and genomic elements can be related to each other by mining pathway, interactions, and functional genomics. Literature mining allowed a first-pass establishment of over 7000 disease-gene relationships. For a new disease or a syndrome of unknown etiology, disorders sharing similar clinical features could be used as a first step to hypothesize gene network connections, and these can prioritize genes that can serve as candidate modifiers for subsequent association studies, particularly after prioritization of potentially harmful polymorphisms within the hypothesized genes. Mapping between clinical features and genes networks may allow for significant reduction of gene polymorphism search space. Achieving this goal fundamentally requires integrating clinical informatics databases with genomics databases, improved disease classification and individual patient descriptions, complete access to biomedical literature and population and genome-scale datasets.

Methods: UC/CCHMC Bioinformatics Tools Box

To obtain reliable hypothesis from omic data, it is effective to integrate interaction from different datasets.



Understanding disease processes fundamentally involves linking genomic variation to clinical phenotype which is challenging because a) disease phenotypes are difficult to ascertain, may be heterogeneous, and can be influenced by environmental factors and b) routine comprehensive characterization of genomic variation in a large cohort of cases and controls is often difficult. It is therefore necessary to focus on variation within high-priority regions of the genome, such as protein-encoding genes or regulatory regions.


Inferring function through genome-scale datasets

Retinitis pigmentosa (RP) is an inherited eye disease that causes visual disability leading to blindness. Environmental factors have been near the top of the suspect list for the variation in disease severity.

Genome-wide scan of promoters (-1 kb) for conserved Crx sites: Crx (cone rod homeobox) is predominantly retina-specific transcription factor and plays an important role in retinal development, function and pathology. Based on the hypothesis that target genes of tissue-specific transcription factors are more likely related to that tissue in terms of expression or function or phenotype. Genome-wide scan for a conserved Crx site resulted in 1627 target genes.

Retinal Diseases: Candidate Prioritization

- 1627 Genes with conserved Crx/Otx2 site in the upstream 1 kb region
- 295 Genes associated with visual perception (GO)
- 505 Genes associated with eye disease
- 313 Genes overexpressed in retina




Predicted Crx-target genes that are "retina-enriched" by integrating expression, gene ontology and disease-association data.

Gene	Name
ABCA4	ATP-binding cassette, sub-family A (ABC1), member 4
ABPA1	Anti-Parkinson protein interacting protein 1
CACMA-9	Calcium channel, voltage-dependent, alpha 1F subunit
CHX10	Calc-10 homeobox domain containing homeobox (C. elegans)
CRX	cone-rod homeobox
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 1
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 2
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 3
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 4
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 5
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 6
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 7
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 8
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 9
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 10
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 11
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 12
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 13
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 14
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 15
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 16
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 17
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 18
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 19
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 20
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 21
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 22
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 23
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 24
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 25
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 26
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 27
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 28
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 29
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 30
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 31
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 32
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 33
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 34
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 35
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 36
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 37
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 38
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 39
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 40
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 41
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 42
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 43
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 44
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 45
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 46
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 47
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 48
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 49
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 50
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 51
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 52
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 53
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 54
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 55
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 56
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 57
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 58
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 59
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 60
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 61
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 62
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 63
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 64
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 65
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 66
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 67
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 68
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 69
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 70
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 71
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 72
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 73
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 74
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 75
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 76
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 77
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 78
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 79
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 80
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 81
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 82
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 83
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 84
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 85
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 86
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 87
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 88
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 89
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 90
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 91
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 92
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 93
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 94
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 95
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 96
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 97
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 98
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 99
CRX17	Cruxine nucleotide binding protein (D. rerio), alpha transducing activity polypeptide 100

Set of 158 retinal-disease mutations

Set of 2254 SNPs (source: NCBI dbSNP)



Can we infer candidate genes through disease attributes, namely affected anatomical systems and symptoms?


40 inherited diseases (OMIM) have retina-related symptoms/lesions

Literature-mining: Genes associated with retinal-phenotypes



Although full implication and biologic significance of the putative candidate genes identified are not yet completely understood, the genes may serve as a platform to further explore relevant mechanisms of pathogenesis and improve the understanding of the molecular basis of blindness. It will be important to discover how these genes relate to blindness.

<http://genometrafac.cchmc.org>




GATACA-Gene Associations to Anatomy & Clinical Abnormalities

We are developing strategies to systematically link clinical features to genomic elements. Diseases can be related to each based on shared etiology, pathophysiology, clinical signs, symptoms and lesions using the UMLS metathesaurus. Genes and genomic elements are related through publicly available functional genomics data and annotations. We hypothesize that for a new disease or a syndrome of unknown etiology, disorders sharing similar clinical features could be used as a first step to identify gene network connections. These networks can be valuable in candidate gene prioritization and can serve as candidate modifiers for subsequent association studies. For exploring the optimal visualization methods, we are collaborating with the Design, Art, Architecture and Planning Department at University of Cincinnati.



<http://polydoms.cchmc.org>



Functional polymorphism scanning for analyzing gene variation in population and patients with variable phenotype holds great promise for future development in the area of personalized medicine.

Conclusions

- Integration of biomedical and clinical data with functional genomics data will enable in spotlighting not only single genes but also entire networks of genes that underlie and modify pathophysiologies. It also serves as an effective filter for candidate genes and variations prioritization for validation.
- Improved data standards, methods and tools are necessary for accessing, integrating and visualizing large-scale data sets that can properly manage the nuances of diversity in genomic and clinical data repositories.

References

- <http://umlskls.nlm.nih.gov/kss/>
- <http://polydoms.cchmc.org>
- <http://genometrafac.cchmc.org>
- <http://cisMols.cchmc.org>
- <http://genome.ucsc.edu>
- <http://abstrainer.cchmc.org>
- <http://www.ncbi.nlm.nih.gov/>
- <http://neikban.nei.nih.gov/>

Acknowledgements

- NIEHS U01 ES11038 Mouse Centers Genomics Consortium
- GATACA Visualization Concept Design: Design ideation_iii students and Mike Zender, Assoc. Prof, DAAP, University of Cincinnati